News & Trends - Pharmaceuticals

Temporary permission granted by TGA to advertise salbutamol puffers and inhalers

Health Industry Hub | January 8, 2020 |
[Total: 1    Average: 5/5]

Until 30 April 2020, the TGA has granted permission for pharmacies to advertise salbutamol products to help Australians suffering respiratory symptoms as a result of the smoke and increased air pollution from bushfires.

Salbutamol (Ventolin, Asmol or Airomir) is an important medicine for the relief of respiratory symptoms associated with asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. Salbutamol in the form of metered dose aerosols (puffers) or dry powders for inhalation is available from pharmacies in Australia with or without prescription. However, salbutamol cannot ordinarily be advertised to the public, even the products that can be purchased over-the-counter (OTC) from pharmacies without prescription.

Smoke and increased air pollution from bushfires, which are currently being experienced in many areas of Australia, can trigger respiratory symptoms. However, pharmacies in bushfire affected areas may experience irregular stock deliveries and people evacuated from their houses may have lost their salbutamol medication or prescription for salbutamol. In this difficult time, it is important that people can be alerted to the availability of OTC salbutamol.

Until 30 April 2020, the TGA has granted permission for pharmacies to advertise that:

  • people with asthma or COPD can obtain salbutamol puffers or dry powder inhalers from a particular pharmacy; and
  • people with asthma or COPD can obtain salbutamol puffers or dry powder inhalers from pharmacies with or without prescription if necessary.

The permission also extends to salbutamol advertising activities conducted or facilitated by evacuation centres and other places dealing with displaced people. It also permits advertising that reminds people with asthma or COPD to, in the event of an evacuation, remember to take the following with them:

  • any salbutamol medicines that they have, and
  • any scripts they have for salbutamol.

Differentiate your business, build thought leadership and boost your network by reaching the Australian Pharma, MedTech and Biotech industry professionals. Health Industry Hub offers unique media solutions to vendors and suppliers servicing the industry. Contact us.

Pharmacies seeking to advertise the availability of OTC salbutamol from their business must ensure that they have adequate stocks before advertising, otherwise the advertising would be considered misleading and in breach of the Therapeutic Goods Advertising Code (Code). There are sanctions and penalties for advertising that does not comply with the Code. Online advertising in particular should be amended or removed quickly should stocks dwindle or become unavailable to avoid the advertising misleading.

Pharmacy staff responding directly to individual queries from patients about the availability of salbutamol or any other medicine is not considered to be advertising.

This permission expires on 30 April 2020, unless otherwise extended. Advertising salbutamol after this date may expose advertisers to sanctions and penalties.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia‚Äôs Pharma, MedTech and Biotech industry professionals and its key stakeholders.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

Marketing Pharma Biotech Healthcare - PRIME Awards 2020 finalists announced

PRIME Awards 2020 finalists announced

Health Industry Hub | August 7, 2020 |

The finalists for PRIME Awards 2020 have been named, with winners to be announced via a virtual ceremony on Thursday […]

More


News & Trends - Pharmaceuticals

Pharma News - New Ventolin inhalers with dose counter reimbursed on the PBS

New Ventolin inhalers with dose counter reimbursed on the PBS

Health Industry Hub | August 7, 2020 |

Pharma News: GSK Australia is pleased to announce that a dose counter has been added to VENTOLIN (salbutamol sulfate) metered […]

More


News & Trends - Medical Technology

MedTech News - Siemens Healthineers to acquire Varian in $16.4bn deal

Siemens Healthineers to acquire Varian in $16.4bn deal

Health Industry Hub | August 5, 2020 |

MedTech News: Siemens Healthineers shall acquire Varian Medical Systems for approximately USD$16.4 billion. Since 2012, Siemens Healthineers and Varian have […]

More


News & Trends - Pharmaceuticals

Pharma News - New anti-cancer drug for prostate cancer

New anti-cancer drug for prostate cancer

Health Industry Hub | August 5, 2020 |

Pharma News: A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis […]

More